| Name | Title | Contact Details |
|---|
Blueprint Medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. Our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. We are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. By focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. We see a substantial opportunity in kinase drug discovery and development to deliver breakthrough medicines that allow patients to live longer with better quality of life and prevent recurrences of disease. Kinases are involved in many hallmarks of tumor biology and are proven cancer drug targets. Currently approved drugs focus on less than 5 percent of known kinases, and the function of most kinases is unknown. Led by a team of industry innovators with a track record of bringing life-changing drugs to market, we believe Blueprint Medicines has the experience and expertise to deliver on the tremendous untapped potential of kinase therapies to improve patients’ lives. We don’t think in small steps. We think in giant leaps. We are driven by the pursuit of new ideas, new innovations, and new ways of thinking.
BioRealty, Inc. is a San Clemente, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Trailblazer Health Enterprises, LLC is a Dallas, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MediStreams provides outsourced Healthcare Revenue Cycle Management (RCM) services for healthcare providers such as health systems, hospitals, clinics, physician groups, labs, and clinics. Despite significant advances in technology, RCM in the United States is unique and extremely complex. Although there has been a push for insurance payments to be made electronically, there are still many that arrive in the form of paper Explanation of Benefits (EOBs) combined with a traditional paper check. The Electronic Remittance Advice (ERAs) do arrive electronically and the funds are deposited to the provider`s bank, but they still must be managed and combined with other payment types to create a file that can be posted into the providers practice management software. MediStreams is now helping the industry embrace new payment technologies that leverage existing credit pipes while managing protected healthcare information. MediStreams` process automates the flow of healthcare payments by creating electronic files customized specifically to post directly to the provider`s practice management system. MediStreams` unique service delivery model accelerates the posting of remittances while eliminating errors associated with manual processing which significantly reduces provider overhead costs. MediStreams` fully HIPAA compliant platform also provides the means for payers to provide a fully reconciled payment to providers in compliance with Section 1104 of the Affordable Care Act (ACA).
Saint Louis Effort for Aids is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.